Longboard Pharmaceuticals Stock EBITDA
Longboard Pharmaceuticals fundamentals help investors to digest information that contributes to Longboard Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Longboard Stock. The fundamental analysis module provides a way to measure Longboard Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Longboard Pharmaceuticals stock.
Longboard |
Longboard Pharmaceuticals Company EBITDA Analysis
Longboard Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Longboard Pharmaceuticals EBITDA | (56.75 M) |
Most of Longboard Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Longboard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Longboard Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (56.75 Million). This is 106.47% lower than that of the Biotechnology sector and 156.67% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.46% higher than that of the company.
Longboard EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Longboard Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Longboard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Longboard Pharmaceuticals by comparing valuation metrics of similar companies.Longboard Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Longboard Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 2.06 B | |||
| Shares Outstanding | 34.44 M | |||
| Shares Owned By Insiders | 1.19 % | |||
| Shares Owned By Institutions | 98.81 % | |||
| Number Of Shares Shorted | 1.93 M | |||
| Price To Book | 8.51 X | |||
| EBITDA | (56.75 M) | |||
| Net Income | (54.42 M) | |||
| Cash And Equivalents | 87.42 M | |||
| Cash Per Share | 5.09 X | |||
| Total Debt | 475 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 11.95 X | |||
| Book Value Per Share | 7.05 X | |||
| Cash Flow From Operations | (50.87 M) | |||
| Short Ratio | 1.27 X | |||
| Earnings Per Share | (2.25) X | |||
| Target Price | 64.0 | |||
| Number Of Employees | 50 | |||
| Beta | 1.09 | |||
| Market Capitalization | 2.34 B | |||
| Total Asset | 50.7 M | |||
| Retained Earnings | (140.56 M) | |||
| Working Capital | 40.45 M | |||
| Net Asset | 50.7 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Longboard Stock
If you are still planning to invest in Longboard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Longboard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |